Intravitreal antiglaucoma treatment: refractive changes and retinal effects in rats

To evaluate the effect of two extended-release intravitreal (IV) hypopressure and neuroprotective treatments on refractive error and the neuroretina in rat eyes with chronic glaucoma. Cohort study. A total of 192 Long–Evans rat right eyes were analyzed: 42 healthy, 25 with glaucoma induced by episcleral vein sclerosis (G-evs), 60 G-evs treated with a single IV brimonidine–Laponite injection (G-evs–Brimonidine), 45 with glaucoma induced by anterior chamber microspheres (G-Ms), and 20 G-Ms treated with two IV latanoprost microsphere injections (G-Ms–Latanoprost). Assessments included intraocular pressure (IOP, rebound tonometry), retinal ganglion cell (RGC) function (electroretinography), diopter power, and neuroretinal structure (peripapillary retinal nerve fiber layer [pRNFL], RGC layer, and whole retina by optical coherence tomography) over 24 weeks. IOP, Latency and amplitude of electroretinography, diopters, thicknesses of the retinal layers. IV-treated glaucomatous eyes showed significantly lower IOP: G-evs–Brimonidine and G-Ms–Latanoprost vs. healthy eyes, and higher ERG b-wave amplitudes (both p < 0.001). All glaucomatous eyes exhibited dioptric power loss vs. healthy. G-evs–Brimonidine stabilized refraction and preserved RGC layer thickness (both p < 0.05). Conversely, G-Ms–Latanoprost caused greater myopization ( p = 0.011) but increased central retinal volume ( p < 0.001) and pRNFL thickness, exceeding even healthy eyes ( p = 0.001). Extended-release IV brimonidine and latanoprost lowered IOP and improved neuroretinal function and structure. A single IV brimonidine injection stabilized refraction and preserved RGC integrity, whereas repeated IV latanoprost injections induced myopization while enhancing central retinal and pRNFL thickness. These findings suggest that sustained-release IV therapy exerts both hypopressure and neuroprotective effects, while repeated injections may also modify ocular refractive status in glaucomatous eyes.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-13
DOI
https://doi.org/10.1038/s41598-026-74370-1
Primary Topic
Glaucoma and retinal disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Intravitreal antiglaucoma treatment: refractive changes and retinal effects in rats

Elena García‐Martín, Silvia Méndez-Martínez, María Jesús Rodrigo, Inés Munuera et al.
Scientific Reports
Glaucoma and retinal disorders
article

Intravitreal antiglaucoma treatment: refractive changes and retinal effects in rats

Elena García‐Martín, Silvia Méndez-Martínez, María Jesús Rodrigo, Inés Munuera, Teresa Martínez, Manuel Subías, Luis Pablo, Javier J. Bermúdez-Cervilla, Claudia Hernández-Barahona
article en

Abstract

To evaluate the effect of two extended-release intravitreal (IV) hypopressure and neuroprotective treatments on refractive error and the neuroretina in rat eyes with chronic glaucoma. Cohort study. A total of 192 Long–Evans rat right eyes were analyzed: 42 healthy, 25 with glaucoma induced by episcleral vein sclerosis (G-evs), 60 G-evs treated with a single IV brimonidine–Laponite injection (G-evs–Brimonidine), 45 with glaucoma induced by anterior chamber microspheres (G-Ms), and 20 G-Ms treated with two IV latanoprost microsphere injections (G-Ms–Latanoprost). Assessments included intraocular pressure (IOP, rebound tonometry), retinal ganglion cell (RGC) function (electroretinography), diopter power, and neuroretinal structure (peripapillary retinal nerve fiber layer [pRNFL], RGC layer, and whole retina by optical coherence tomography) over 24 weeks. IOP, Latency and amplitude of electroretinography, diopters, thicknesses of the retinal layers. IV-treated glaucomatous eyes showed significantly lower IOP: G-evs–Brimonidine and G-Ms–Latanoprost vs. healthy eyes, and higher ERG b-wave amplitudes (both p < 0.001). All glaucomatous eyes exhibited dioptric power loss vs. healthy. G-evs–Brimonidine stabilized refraction and preserved RGC layer thickness (both p < 0.05). Conversely, G-Ms–Latanoprost caused greater myopization ( p = 0.011) but increased central retinal volume ( p < 0.001) and pRNFL thickness, exceeding even healthy eyes ( p = 0.001). Extended-release IV brimonidine and latanoprost lowered IOP and improved neuroretinal function and structure. A single IV brimonidine injection stabilized refraction and preserved RGC integrity, whereas repeated IV latanoprost injections induced myopization while enhancing central retinal and pRNFL thickness. These findings suggest that sustained-release IV therapy exerts both hypopressure and neuroprotective effects, while repeated injections may also modify ocular refractive status in glaucomatous eyes.

Scientific Reports
Universidad de Zaragoza (ES), Hospital Universitario Miguel Servet (ES), Instituto de Investigación Sanitaria Aragón (ES)
Ministerio de Ciencia e Innovación, Universidad de Zaragoza, Gobierno de Aragón, Instituto de Salud Carlos III, European Regional Development Fund, Agencia Estatal de Investigación
Good health and well-being
Glaucoma and retinal disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon